Skip to content
value.today
Prelude Therapeutics Inc. logo

Prelude Therapeutics Inc.

🇺🇸 Newark, Delaware, USABiotechnologyFounded 2016
Total raised
$115 M
4 rounds on record
Latest round
$50 M
Aug 2020
First round on record
Jun 2016
Today
Went public
See the company page

Prelude Therapeutics Inc. is listed today as Prelude Therapeutics Incorporated: market value, financials and filings are on its company page.

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Prelude Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2020$50 MNo. 4$50 to $250 million

Prelude Therapeutics Inc.: Raise no. 4, Aug 2020

Investors in this round

7 investors had bought by the notice of Aug 28, 2020: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Prelude Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$50 M of $50 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew C. Combs · Executive Officer
  • Brian C. Piper · Executive Officer
  • Christopher C. Pierce · Executive Officer
  • David C. Mauro · Executive Officer
  • Deborah C. Morosini · Executive Officer
  • Krishna Vaddi · Executive Officer, Director
  • Peggy C. Scherle · Executive Officer
  • David Bonita · Director
  • Kelvin Neu · Director
  • Mardi C. Dier · Director
  • Paul Friedman · Director
  • Victor Sandor · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Krishna Vaddi, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 28, 2020. Read the notice at the SEC.

equitySEC
May 2019$30 MNo. 3$10 to $50 million

Prelude Therapeutics Inc.: Raise no. 3, May 2019

Investors in this round

6 investors had bought by the notice of Jun 17, 2019: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Prelude Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$30 M of $60 M offered; $30 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Mauro · Executive Officer
  • Krishna Vaddi · Executive Officer, Director
  • Peggy Scherle · Executive Officer
  • David Bonita · Director
  • Kelvin Neu · Director
  • Paul Friedman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Kris Vaddi, Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 17, 2019. Read the notice at the SEC.

equitySEC
Oct 2017$30 MNo. 2$10 to $50 million

Prelude Therapeutics Inc.: Raise no. 2, Oct 2017

Investors in this round

7 investors had bought by the notice of Aug 17, 2018: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Prelude Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$30 M of $30 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Juan Luengo · Executive Officer · Vice President of Issuer
  • Krishna Vaddi · Executive Officer, Director · Director, Chief Executive Officer, President and Secretary of Issuer
  • David Bonita · Director · Director of Issuer
  • Kelvin Neu · Director · Director of Issuer
  • Paul Friedman · Director · Director of Issuer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Krishna Vaddi, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Aug 17, 2018. Read the notice at the SEC.

equitySEC
Jun 2016$5 MNo. 1$2 to $10 million

Prelude Therapeutics Inc.: Raise no. 1, Jun 2016

Investors in this round

8 investors had bought by the notice of Jul 11, 2016: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 7 investors are named for Prelude Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Krishna Vaddi · Executive Officer, Director · Director, Chief Executive Officer, President and Secretary of Issuer
  • David Bonita · Director · Director of Issuer
  • Paul Friedman · Director · Director of Issuer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Krishna Vaddi, Director, CEO, President and Secretary. Source: SEC Form D, newest notice filed Jul 11, 2016. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Prelude Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2020).

    SEC Form D · Aug 2020

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Aug 2020

That is all the official record says: Prelude Therapeutics Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Prelude Therapeutics Inc. are on record.

Investors#

7 named in official filings. Open an investor to see everything it has backed.

Investors in Prelude Therapeutics Inc.
InvestorKindAmountRoundRoleSource
667, L.P.Fund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner, director (Form 3, 2020)SEC Form 3
Baker Bros. Advisors (GP) LLCFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner, director (Form 3, 2020)SEC Form 3
Baker Bros. Advisors LPFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner, director (Form 3, 2020)SEC Form 3
Baker Brothers Life Sciences LPFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner, director (Form 3, 2020)SEC Form 3
Orbimed Advisors LLCFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner, director (Form 3, 2020)SEC Form 3
OrbiMed Capital GP VI LLCFund or asset managernot statednot statedHeld Series A, B and C preferred stock, 10% owner, director (Form 3, 2020)SEC Form 3
Paul A. FriedmanPersonnot statednot statedHeld Series A and B preferred stock, director (Form 3, 2020)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 8 investors.

Largest shareholders today

Institutions holding Prelude Therapeutics Incorporated shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Prelude Therapeutics Inc.
NameRoleNamed in
Andrew C. CombsExecutive officerAug 2020
Brian C. PiperExecutive officerAug 2020
Christopher C. PierceExecutive officerAug 2020
David C. MauroExecutive officerAug 2020
Deborah C. MorosiniExecutive officerAug 2020
Krishna VaddiExecutive officerAug 2020
Peggy C. ScherleExecutive officerAug 2020
David MauroExecutive officerJun 2019
Peggy ScherleExecutive officerJun 2019
Juan LuengoVice President of IssuerAug 2018
David BonitaDirectorAug 2020
Kelvin NeuDirectorAug 2020
Krishna VaddiDirectorAug 2020
Mardi C. DierDirectorAug 2020
Paul FriedmanDirectorAug 2020
Victor SandorDirectorAug 2020

Went public since 2020. Its SEC number is that of a company listed on a stock exchange.